Rufinamide

Rank #441 of 500 drugs by total cost

Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026

$18.0M

Total Cost

Share:

8,793

Total Claims

$18.0M

Total Cost

464

Prescribers

$2,044

Cost per Claim

23

Beneficiaries

9,381

30-Day Fills

$39K

Avg Cost/Provider

19

Avg Claims/Provider

Share of Medicare Part D Spending

0.01%

of total Medicare Part D spending

$18.0M of $275.65B

Top Prescribers by Cost

Top 10 prescribers of $18.0M total

🔎 Data Overview

💰

At $2,044 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.

👤

Average cost of $781,357 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.

Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.

Top Prescribers of Rufinamide

#ProviderSpecialtyLocationClaimsCost
1David LabinerNeurologyTucson, AZ90$329K
2Deborah ZielinskiNurse PractitionerChicago, IL134$266K
3Myriam AbdennadherNeurologyBoston, MA44$261K
4David FriedmanNeurologyMineola, NY41$244K
5Kimberly KonieczkiNurse PractitionerErie, PA35$210K
6Deborah ZielinskiNurse PractitionerChicago, IL42$210K
7Paul AtkinsonNeurologyRoseville, MN38$195K
8Kristen BatsonNurse PractitionerOrlando, FL15$184K
9Nicholas ZendlerNeurologyGarden City, MI40$174K
10Christine BacaNeurologyAurora, CO24$166K
11Jennifer VickersNeurologyAlbuquerque, NM110$158K
12Toufic FakhouryNeurologyLexington, KY87$157K
13Ignacio Pita GarciaNeurologyGuaynabo, PR37$144K
14Ruth DekkerNurse PractitionerPocatello, ID35$143K
15Maryam MosharrafNurse PractitionerLexington, KY26$134K

Top prescribers ranked by total cost for this drug in 2023.

Related Drugs by Cost

#DrugTotal CostClaims
438Enasidenib Mesylate (Idhifa)$18.1M554
439Posaconazole (Posaconazole)$18.0M7,163
440Metronidazole (Metronidazole)$18.0M405,967
441Rufinamide (Rufinamide)$18.0M8,793
442Istradefylline (Nourianz)$17.8M7,061
443Encorafenib (Braftovi)$17.6M1,209
444Cladribine (Mavenclad)$17.5M228

Related Analysis

Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology